Figure 3.
LMO4 levels are significantly associated with patient overall survival (OS) in different tumor stages and sizes. (A,B) OS of patients with high or low-LMO4 expression when further divided into tumor-node-metastasis (TNM) I–II and TNM III–IV subgroups; (C,D) OS rates of patients with tumor size ﹤3 cm and tumor size ≥3 cm, respectively.